Matching articles for "bezlotoxumab"
Issue 1677 · May 29, 2023 Free
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence

The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection…

Med Lett Drugs Ther. 2023 May 29; 65(1677):81-2 doi:10.58347/tml.2023.1677a
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication. Neither product is approved for acute treatment of CDI.
Issue 1671 · March 6, 2023
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence

The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):35-6 doi:10.58347/tml.2023.1671b
The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic treatment for a recurrent episode of CDI in adults. Rebyota is the first microbiome-based treatment to be approved for this indication. It is not approved for initial treatment of CDI. Fecal microbiota transplantation (FMT) has been used in patients with multiple CDI recurrences.
Issue 1632 · September 6, 2021
Treatment of Clostridioides difficile Infection

Clostridioides (formerly Clostridium ) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.

Med Lett Drugs Ther. 2021 Sep 6; 63(1632):137-41
Clostridioides (formerly Clostridium ) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Issue 1517 · March 27, 2017
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection

The FDA has approved the fully human monoclonal antibody bezlotoxumab ( Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile infection (CDI) in adults…

Med Lett Drugs Ther. 2017 Mar 27; 59(1517):49-50
The FDA has approved the fully human monoclonal antibody bezlotoxumab ( Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile infection (CDI) in adults with CDI at high risk for recurrence. It is the first drug to be approved for this indication.